Ovulation trigger replacement as a method for preventing ovarian hyperstimulation syndrome


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

The current data available in the literature on the prevention of ovarian hyperstimulation syndrome (OHSS) by replacing an ovulation trigger by a gonadotropin-releasing hormone (GnRH) agonist were studied. OHSS is one of the most dangerous complications of controlled superovulation induction. Ovulation trigger replacement should be noted among the variety of methods for preventing this complication. The results of systematic reviews of randomized clinical trials have convincingly shown that the GnRH agonist as an ovulation trigger decreases the incidence of OHSS. There is now no consensus on criteria for the prescription of a GnRH agonist and its effect on conception rates.

Full Text

Restricted Access

About the authors

B. A Martazanova

Academician V.I. Kulakov Research Center of Obstetrics, Gynecology and Perinatology, Ministry of Health of Russia

Email: bellamart88@mail.ru
graduate student

N. G Mishieva

Academician V.I. Kulakov Research Center of Obstetrics, Gynecology and Perinatology, Ministry of Health of Russia

Email: nondoc555@mail.ru
MD, Senior researcher of 1st gynecology department

A. N Abubakirov

Academician V.I. Kulakov Research Center of Obstetrics, Gynecology and Perinatology, Ministry of Health of Russia

Email: nondoc555@yahoo.com
PhD, Head of 1st gynecology department

References

  1. Humaidan P., Quartarolo J., Papanikolaou E.G. Preventing ovarian hyperstimulation syndrome: guidance for the clinician. Fertil. Steril. 2010; 94(2): 389-400.
  2. Papanikolaou E.G., Pozzobon C., Kolibianakis E.M., Camus M., Tournaye H., Fatemi H.M. et al. Incidence and prediction of ovarian hyperstimulation syndrome in women undergoing gonadotropin-releasing hormone antagonist in vitro fertilization cycles. Fertil. Steril. 2006; 85(1): 112-20.
  3. Acevedo B., Gomez-Palomares J.L., Ricciarelli E., Hernández E.R. Triggering ovulation with gonadotropin-releasing hormone agonists does not compromise embryo implantation rates. Fertil. Steril. 2006; 86(6): 1682-7.
  4. Engmann L., DiLuigi A., Schmidt D., Nulsen J., Maier D., Benadiva C. The use of gonadotropin-releasing hormone (GnRH) agonist to induce oocyte maturation after cotreatment with GnRH antagonist in high-risk patients undergoing in vitro fertilization prevents the risk of ovarian hyperstimulation syndrome: a prospective randomized controlled study. Fertil. Steril. 2008; 89(1): 84-91.
  5. Kol S. Luteolysis induced by a gonadotropin-releasing hormone agonist is the key to prevention of ovarian hyperstimulation syndrome. Fertil. Steril. 2004; 81(1): 1-5.
  6. Khaldoun Sharif, Arri Coomarasamy, eds. Assisted reproduction techniques: challenges and management options. Wiley-Blackwell; 2012.
  7. Devroey P., Boostanfar R., Koper N.P., Mannaerts B.M., Ijzerman-Boon P.C., Fauser B.C. A double-blind, non-inferiority RCT comparing corifollitropin alfa and recombinant FSH during the first seven days of ovarian stimulation using a GnRH antagonist protocol. Hum. Reprod. 2009; 24: 3063-72.
  8. Papanikolaou E.G., Tournaye H., Verpoest W., Camus M., Vernaeve V., Van Steirteghem A., Devroey P. Early and late ovarian hyperstimulation syndrome: early pregnancy outcome and profile. Hum. Reprod. 2005; 20(3): 636-41.
  9. Корнеева И.Е., Иванова А.В., Баркалина Н.В. Синдром гиперстимуляции яичников: профилактика, диагностика, лечение (обзор литературы). Проблемы репродукции. 2004; 10(1): 43-50
  10. Damewood M.D., Shen W., Zacur H.A., Schlaff W.D., Rock J.A., Wallach E.E. Disappearance of exogenously administered human chorionic gonadotropin. Fertil. Steril. 1989; 52(3): 398-400.
  11. Fauser B.C., de Jong D., Olivennes F., Wramsby H., Tay C., Itskovitz-Eldor J., van Hooren H.G. Endocrine profiles after triggering of final oocyte maturation with GnRH agonist after cotreatment with the GnRH antagonist ganirelix during ovarian hyperstimulation for in vitro fertilization. J. Clin. Endocrinol. Metab. 2002; 87(2): 709-15.
  12. Itskovitz J., Boldes R., Barlev A., Erlik Y., Kahana L., Brandes J.M. The induction of LH surge and oocyte maturation by GnRH analogue (buserelin) in women undergoing ovarian stimulation for in vitro fertilisation. Gynecol. Endocrinol. 1988; 2(Suppl. 2): 165.
  13. Imoedemhe D.A., Chan R.C., Sigue A.B., Pacpaco E.L., Olazo A.B. A new approach to the management of patients at risk of ovarian hyperstimulation in an in-vitro fertilization programme. Hum. Reprod. 1991; 6(8): 1088-91.
  14. Lewit N., Kol S., Manor D., Itskovitz-Eldor J. Comparison of gonadotrophin-releasing hormone analogues and human chorionic gonadotrophin for the induction of ovulation and prevention of ovarian hyperstimulation syndrome: a case-control study. Hum. Reprod. 1996; 11: 1399-402.
  15. Itskovitz-Eldor J., Kol S., Mannaerts B. Use of a single bolus of GnRH agonist triptorelin to trigger ovulation after GnRH antagonist ganirelix treatment in women undergoing ovarian stimulation for assisted reproduction, with special reference to the prevention of ovarian hyperstimulation syndrome: preliminary report: short communication. Hum. Reprod. 2000; 15(9): 1965-8.
  16. Babayof R., Margalioth E.J., Huleihel M., Amash A., Zylber-Haran E., Gal M. et al. Serum inhibin A, VEGF and TNFalpha levels after triggering oocyte maturation with GnRH agonist compared with HCG in women with polycystic ovaries undergoing IVF treatment: a prospective randomized trial. Hum. Reprod. 2006; 21(5):1260-5.
  17. Humaidan P., Bredkjaer H.E., Bungum L., Bungum M., Grondahl M.L., Westergaard L., Andersen C.Y. GnRH agonist (Buserelin) or hCG for ovulation induction in GnRH antagonist IVF/ICSI cycles: a prospective randomised study. Hum. Reprod. 2005; 20: 1213-20.
  18. Melo M., Busso C.E., Bellver J., Alama P., Garrido N., Meseguer M. et al. GnRH agonist versus recombinant HCG in an oocyte donation programme: a randomized, prospective, controlled, assessor-blind study. Reprod. Biomed. Online. 2009; 19(4): 486-92.
  19. Galindo A., Bodri D., Guillen J.J., Colodron M., Vernaeve V., Coll O. Triggering with HCG or GnRH agonist in GnRH antagonist treated oocyte donation cycles: a randomised clinical trial. Gynecol. Endocrinol. 2009; 25: 60-6.
  20. Manzanares M.A., Gómez-Palomares J.L., Ricciarelli E., Hernández E.R. Triggering ovulation with gonadotropin-releasing hormone agonist in in vitro fertilization patients with polycystic ovaries does not cause ovarian hyperstimulation syndrome despite very high estradiol levels. Fertil. Steril. 2010; 93: 1215-9.
  21. Griesinger G., von Otte S., Schroer A., Ludwig A.K., Diedrich K., Al-Hasani S., Schultze-Mosgau A. Elective cryopreservation of all pronuclear oocytes after GnRH agonist triggering of final oocyte maturation in patients at risk of developing OHSS: a prospective, observational proof-of-concept study. Hum. Reprod. 2007; 22: 1348-52.
  22. DiLuigi A.J., Engmann L., Schmidt D.W., Maier D.B., Nulsen J.C., Benad iva C.A. Gonadotropin-releasing hormone agonist to induce final oocyte maturation prevents the development of ovarian hyperstimulation syndrome in high-risk patients and leads to improved clinical outcomes compared with coasting. Fertil. Steril. 2010; 94: 1111-4.
  23. D’Angelo A., Brown J., Amso N.N. Coasting (withholding gonadotrophins) for preventing ovarian hyperstimulation syndrome. Cochrane Database Syst Rev. 2011; (2):CD002811, (6):CD002811.
  24. Griesinger G., Diedrich K., Devroey P., Kolibianakis E.M. GnRH agonist for triggering final oocyte maturation in the GnRH antagonist ovarian hyperstimulation protocol: a systematic review and meta-analysis. Hum. Reprod. 2006; 12(2): 159-68.
  25. Youssef M.A., Van der Veen F., Al-Inany H.G., Griesinger G., Mochtar M.H., Aboulfoutouh I. et al. Gonadotropin-releasing hormone agonist versus HCG for oocyte triggering in antagonist assisted reproductive technology cycles. Cochrane Database Syst. Rev. 2011; (1): CD008046.
  26. Griesinger G., Schultz L., Bauer T., Broessner A., Frambach T., Kissler S. Ovarian hyperstimulation syndrome prevention by gonadotropin-releasing hormone agonist triggering of final oocyte maturation in a gonadotropin-releasing hormone antagonist protocol in combination with a ‘‘freeze-all’’ strategy: a prospective multicentric study. Fertil. Steril. 2011; 95: 2029-33.
  27. Parneix I., Emperaire J.C., Ruffie A. Triggering of ovulation, using different regimen of gonadotropin-releasing hormone agonist. Gynecol. Obstet. Fertil. 2001; 29(2): 100-5.
  28. Lee T.H., Liu C.H., Huang C.C., Wu Y.L., Shih Y.T., Ho H.N. et al. Serum anti-M-Müllerian hormone and estradiol levels as predictors of ovarian hyperstimulation syndrome in assisted reproduction technology cycles. Hum. Reprod. 2008; 23(1): 160-7.
  29. Kwee J., Schats R., McDonnell J., Themmen A., de Jong F., Lambalk C. Evaluation of anti-Müllerian hormone as a test for the prediction of ovarian reserve. Fertil. Steril. 2008; 90(3): 737-43.
  30. Kwee J., Elting M.E., Schats R., McDonnell J., Lambalk C.B. Ovarian volume and antral follicle count for the prediction of low and hyper responders with in vitro fertilization. Reprod. Biol. Endocrinol. 2007; 5: 9.
  31. Humaidan P., Kol S., Papanikolaou E.G. GnRH agonist for triggering of final oocyte maturation: time for a change of practice? Hum. Reprod. 2011; 17(4): 510-24.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies